Literature DB >> 16826431

Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer.

Christian F Singer1, Gernot Hudelist, Ingrid Walter, Ernst Rueckliniger, Klaus Czerwenka, Ernst Kubista, Ambros V Huber.   

Abstract

Transglutaminase-2 is involved in the physiological regulation of cell growth, but has also been associated with a number of cancer-associated features such as cell adhesion, metastasis and extracellular matrix modulation. Despite its importance in tumor cell progression and survival, relatively little is known about its expression in human malignancies. We have therefore investigated the transglutaminase-2 expression pattern in breast and ovarian cancer by using tissue arrays which contained 57 invasive breast cancer biopsies and 62 ovarian cancers, and compared it to transglutaminase-2 protein levels in normal human tissues. By using immunohistochemistry, transglutaminase-2 protein was detected in 48 of 57 breast tumors (84%), with epithelial expression in 26 of 41 (63%) ductal invasive carcinomas and in all 6 (100%) lobular invasive carcinomas. Stromal transglutaminase-2 was present in 14 of 41 (34%) ductal subtypes and in 4 of 6 (67%) lobular subtypes, which is in sharp contrast to the infrequent expression in normal breast stroma (P<0.001, Mann-Whitney test) and somewhat also in normal breast epithelium (P = 0.065, Mann-Whitney test). In most other human tissues, transglutaminase-2 protein was less frequent and usually confined to either the epithelium or in adjacent stroma. In ovarian tumors, the protein was detected in 36 of the 62 cases (58%), and seen in all histological subtypes. Taken together, we have demonstrated increased transglutaminase-2 protein expression in both malignant breast epithelium and surrounding stroma, although its selective spatial expression pattern in normal tissues also indicates a physiological role in stromal-epithelial interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826431     DOI: 10.1007/s10585-006-9015-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  25 in total

Review 1.  Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.

Authors:  D Aeschlimann; V Thomazy
Journal:  Connect Tissue Res       Date:  2000       Impact factor: 3.417

2.  Induction and activation of tissue transglutaminase during programmed cell death.

Authors:  L Fesus; V Thomazy; A Falus
Journal:  FEBS Lett       Date:  1987-11-16       Impact factor: 4.124

3.  Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line.

Authors:  J A Han; S C Park
Journal:  J Cancer Res Clin Oncol       Date:  1999       Impact factor: 4.553

4.  Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis.

Authors:  K Sakai; W H Busby; J B Clarke; D R Clemmons
Journal:  J Biol Chem       Date:  2000-12-19       Impact factor: 5.157

5.  Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses.

Authors:  Phil Stephens; Pascale Grenard; Pascale Aeschlimann; Martin Langley; Emma Blain; Rachael Errington; David Kipling; David Thomas; Daniel Aeschlimann
Journal:  J Cell Sci       Date:  2004-06-15       Impact factor: 5.285

6.  Tissue transglutaminase mRNA expression in apoptotic cell death.

Authors:  E B Volokhina; R Hulshof; C Haanen; I Vermes
Journal:  Apoptosis       Date:  2003-12       Impact factor: 4.677

7.  Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death.

Authors:  Tamara Milakovic; Janusz Tucholski; Eric McCoy; Gail V W Johnson
Journal:  J Biol Chem       Date:  2003-12-11       Impact factor: 5.157

Review 8.  Pathomechanisms in celiac disease.

Authors:  Walburga Dieterich; Birgit Esslinger; Detlef Schuppan
Journal:  Int Arch Allergy Immunol       Date:  2003-10       Impact factor: 2.749

9.  High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells.

Authors:  K Mehta
Journal:  Int J Cancer       Date:  1994-08-01       Impact factor: 7.396

10.  Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin.

Authors:  R A Jones; B Nicholas; S Mian; P J Davies; M Griffin
Journal:  J Cell Sci       Date:  1997-10       Impact factor: 5.285

View more
  16 in total

1.  Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells.

Authors:  Marc A Antonyak; Bo Li; Lindsey K Boroughs; Jared L Johnson; Joseph E Druso; Kirsten L Bryant; David A Holowka; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

2.  The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.

Authors:  Garima Singh; Jingwen Zhang; Yilun Ma; Richard A Cerione; Marc A Antonyak
Journal:  J Biol Chem       Date:  2016-02-18       Impact factor: 5.157

3.  A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration.

Authors:  Lindsey K Boroughs; Marc A Antonyak; Jared L Johnson; Richard A Cerione
Journal:  J Biol Chem       Date:  2011-09-06       Impact factor: 5.157

4.  Prognostic role of tissue transglutaminase 2 in colon carcinoma.

Authors:  María Jesús Fernández-Aceñero; Sofía Torres; Irene Garcia-Palmero; Cristina Díaz Del Arco; J Ignacio Casal
Journal:  Virchows Arch       Date:  2016-09-13       Impact factor: 4.064

5.  A mechanism for the upregulation of EGF receptor levels in glioblastomas.

Authors:  Jingwen Zhang; Marc A Antonyak; Garima Singh; Richard A Cerione
Journal:  Cell Rep       Date:  2013-06-13       Impact factor: 9.423

6.  Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion.

Authors:  Marc A Antonyak; Bo Li; Andrew D Regan; Qiyu Feng; Stephanie S Dusaban; Richard A Cerione
Journal:  J Biol Chem       Date:  2009-04-29       Impact factor: 5.157

7.  TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.

Authors:  Jun Fu; Qun-ying Yang; Ke Sai; Fu-rong Chen; Jesse C S Pang; Ho-keung Ng; Aij-lie Kwan; Zhong-ping Chen
Journal:  Neuro Oncol       Date:  2013-07-21       Impact factor: 12.300

8.  Transglutaminase 2 in cancer.

Authors:  Lei Huang; A-Man Xu; Wei Liu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

9.  TGM2: a cell surface marker in esophageal adenocarcinomas.

Authors:  Deborah T Leicht; Tasneem Kausar; Zhuwen Wang; Daysha Ferrer-Torres; Thomas D Wang; Dafydd G Thomas; Jules Lin; Andrew C Chang; Lin Lin; David G Beer
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

10.  Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.

Authors:  Jasmeet Assi; Gunjan Srivastava; Ajay Matta; Martin C Chang; Paul G Walfish; Ranju Ralhan
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.